Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Ranks among the top 15% companies globally
Dilip Shanghvi to continue as the Executive Chairman of the Board
This strategic expansion marks a significant step in the company's global growth strategy
25 women students to receive internship, training, and mentorship in Life Sciences segment
Subscribe To Our Newsletter & Stay Updated